BioWorld

Jan. 29, 2007

View Archived Issues

Aranesp Data Eclipse Amgen's Fourth-Quarter Revenue Growth

Despite topping revenue estimates for the fourth quarter, Amgen's Inc.'s stock slipped more than $3 on news of unsettling Phase III Aranesp data. (BioWorld Today) Read More

Xcellerex Series B Gets $20M For FlexFactory Drug System

Read More

Opening The Risk Debate Crucial For Biotech's Future

Read More

Bush Backs Biofuel Use Yet Again In Address To Nation

Read More

Other News To Note

Read More

Clinic Roundup

Read More